Today’s news: Weston, MA-based Biogen Idec, the largest maker of injectable treatments for multiple sclerosis, met its goals in a second clinical trial for an oral pill to treat the disease. The pill reduced flare-ups by 44 percent when taken twice per day, and by 51 percent if taken three times a day. Bedford, MA-based … Continue reading “Today’s Xconomy Report: Biogen Idec Meets Goals in Clinical Trial, iRobot Layoffs, $1M Awarded by MassChallenge, and Bay State Venture Capital Earnings”
Category: National
Report: Gilt Picking Up Troubled Daily Deals Site BuyWithMe
[Updated 10/28/11 2:00 p.m. See below.] According to BetaBeat, fashion site Gilt Groupe is in the final stages of acquiring its New York neighbor BuyWithMe, a daily deals site that made six acquisitions this year and expanded to Seattle—but then started showing signs of distress. Just last week, reports emerged that BuyWithMe, which started in Boston, … Continue reading “Report: Gilt Picking Up Troubled Daily Deals Site BuyWithMe”
Repligen Buys Novozymes Unit, Expanding Product Base and Manufacturing Capacity
After the stock market closed last night, Waltham, MA-based Repligen (NASDAQ: [[ticker:RGEN]]) announced that it will buy a Swedish unit of Novozymes A/S, the Danish maker of industrial-biotech products, for 17 million euros, or about $22.7 million cash, plus 5 million euros ($5.6 million) in potential milestone payments. The unit, called Novozymes Biopharma Sweden, makes … Continue reading “Repligen Buys Novozymes Unit, Expanding Product Base and Manufacturing Capacity”
Editor’s Picks: Xconomy Boston’s Top 20 Stories of the Third Quarter
All this talk about quarterly earnings and venture stats reminded me: I never posted my favorite stories from Xconomy Boston’s third quarter. Yes, I know it’s almost the end of October, and the third quarter ended a month ago. I must have been traumatized by the collapse of the Red Sox or something (is baseball … Continue reading “Editor’s Picks: Xconomy Boston’s Top 20 Stories of the Third Quarter”
Vinod Khosla Helps Startup Entrepreneurs Think Bigger
I had been planning to talk in today’s column about the shortcomings of the Google Chromebook, which are numerous. But I’m in too good of a mood this week to play the critic, partly because of a terrific Silicon Valley event that I attended Tuesday night called Get Bigger! With Vinod Khosla. So instead, I’m … Continue reading “Vinod Khosla Helps Startup Entrepreneurs Think Bigger”
New Genzyme CEO, Biogen Scores in 2nd MS Pill Trial, Nanotech Drug Startups Nab Funds, & More Boston-Area Life Sciences News
It was a meaty New England life sciences week, with clinical advances, new funding, CEO hires, and acquisitions headlines. —Sanofi hired David Meeker as the new CEO of its Cambridge, MA-based Genzyme unit. Meeker, who got started at the company in 1994, will move into his new role on November 1 and will lead the … Continue reading “New Genzyme CEO, Biogen Scores in 2nd MS Pill Trial, Nanotech Drug Startups Nab Funds, & More Boston-Area Life Sciences News”
Ask Bill Gates Anything: Being a Billionaire is Strange, Microsoft Co-Founder Tells Students
How’s the life of a billionaire? “Quite strange,” says Bill Gates, who fielded questions from University of Washington students on Thursday evening as part of a lecture on the future of computing. Gates’ talk, at a packed hall in the UW’s computer science building, focused on some areas where he thinks cheap, powerful computing will … Continue reading “Ask Bill Gates Anything: Being a Billionaire is Strange, Microsoft Co-Founder Tells Students”
PacBio Posts Flat Revenues in Q3, Names Mike Hunkapiller New Executive Chairman
Pacific Biosciences saw its sales flatten in its second quarter on the market with a new breed of DNA sequencing instrument, and now it’s shuffling things around a bit on the org chart to see if it can kickstart its growth. The Menlo Park, CA-based company (NASDAQ: [[ticker:PACB]]) said today it generated $10.5 million in … Continue reading “PacBio Posts Flat Revenues in Q3, Names Mike Hunkapiller New Executive Chairman”
Vertex Flips Into the Black for First Time, as Hepatitis C Drug Beats Expectations Again
Vertex Pharmaceuticals has tallied up an amazing amount of red ink in its 22-year history, but now it can say that all those long R&D years have created a profitable business. The Cambridge, MA-based biotech company (NASDAQ: [[ticker:VRTX]]) said today that it generated $659 million in total revenues, and turned a profit of $221 million … Continue reading “Vertex Flips Into the Black for First Time, as Hepatitis C Drug Beats Expectations Again”
In a Detour From Device Strategy, Zogenix Edges Closer to New Drug Application
San Diego-based Zogenix, a specialty pharma that has been selling its first product (a fast-acting migraine drug in a single-dose injector) for 22 months, is getting ready to diversify its portfolio. As we reported in August, Zogenix successfully completed its late-stage safety and efficacy trials for an extended-release formulation of the painkilling drug hydrocodone bitartrate … Continue reading “In a Detour From Device Strategy, Zogenix Edges Closer to New Drug Application”
Hatch Detroit Business Contest Down to Four Finalists; Voting Ends Nov. 2
The ideas have been pitched, the public cast their votes online and through social media for the semi-finalists, and now the Hatch Detroit retail business contest is in its final stage. This is the hard part, where we choose the winner. Will it be the wine bar or the tea room? The pop-up furniture store … Continue reading “Hatch Detroit Business Contest Down to Four Finalists; Voting Ends Nov. 2”
Redfin Adds $14.8M to Expand Online Real Estate Brokerage to New Markets
[Updated 12:20 pm Pacific with correction] Redfin, the Seattle-based online real estate brokerage, says it has raised $14.8 million led by new investor Globespan Capital Partners. Redfin says the new round of financing, which pushes its total venture tally to about $46 million, will be used for R&D spending and expansion into new markets. At … Continue reading “Redfin Adds $14.8M to Expand Online Real Estate Brokerage to New Markets”
Sencha, Subtext, Sociable Labs: Bay Area BizTech News by the Numbers
Time for our periodic, data-driven roundup of business and technology news around San Francisco Bay. $151 million—The price Google paid to acquire restaurant review aggregator Zagat back in September, according to a regulatory filing examined by Reuters. $135 million—Total financing raised to date by San Jose-based display maker Prysm, according to an announcement today. Xconomy … Continue reading “Sencha, Subtext, Sociable Labs: Bay Area BizTech News by the Numbers”
Massachusetts Startup Investing Rose to $253.8M Last Month, Charged Up By Boston-Power’s $125M
There seems to be a theme in Massachusetts venture investing right now. Things aren’t quite as hot as they were earlier this year, but are still trumping last year’s numbers for the same period. That’s what my colleague Greg noted about the MoneyTree report for Q3 2011 venture investing. And that’s what I’ve observed here … Continue reading “Massachusetts Startup Investing Rose to $253.8M Last Month, Charged Up By Boston-Power’s $125M”
Agradis Takes Root, Illumina Cuts Back, Verenium Arranges Financing, & More San Diego Life Sciences News
It was another big week for life sciences news in San Diego, with interesting developments in agricultural biotech, industrial biotech, and genomic sequencing. This is our wrap up of what you need to know. —San Diego’s Synthetic Genomics spun out a new San Diego-based agricultural biotech, Agradis, with $20 million in Series A financing and … Continue reading “Agradis Takes Root, Illumina Cuts Back, Verenium Arranges Financing, & More San Diego Life Sciences News”
Portola Grabs $45M Upfront From Biogen Idec to Develop Autoimmune Drugs
South San Francisco-based Portola Pharmaceuticals has formed a lucrative alliance today with Biogen Idec (NASDAQ: [[ticker:BIIB]]) to co-develop drugs for autoimmune diseases, seeking to stop the immune system from attacking healthy tissues like a virus. Under the deal, Portola is granting Weston, MA-based Biogen Idec an exclusive worldwide license to co-develop oral pills that block … Continue reading “Portola Grabs $45M Upfront From Biogen Idec to Develop Autoimmune Drugs”
Sloan-Kettering Spinoff Adjuvance Gains Traction For Vaccine Tech
It’s rare to see an entrepreneur cheering for a direct rival, but that’s exactly what’s been happening over the last week or so in New York. It started on October 18, when shares of Boston-based Agenus (NASDAQ: [[ticker:AGEN]]) jumped 65 percent to $4.43 on news that a GlaxoSmithKline (NYSE: [[ticker:GSK]]) malaria vaccine containing an ingredient that … Continue reading “Sloan-Kettering Spinoff Adjuvance Gains Traction For Vaccine Tech”
BIND and Selecta Pull in $50M from Russian Fund Seeking to Advance Nano-Drugs
Two Boston-area startups—both of which emanated from the lab of MIT bioengineer and entrepreneur Bob Langer—announced today that they secured $25 million a piece in funding from Rusnano, a $10 billion Russian Federation fund that supports nanotechnology startups. The money went to Watertown, MA-based Selecta Biosciences and Cambridge, MA-based BIND Biosciences. Each company also added … Continue reading “BIND and Selecta Pull in $50M from Russian Fund Seeking to Advance Nano-Drugs”
WA Companies Raked in Nearly $32M in September Deals
Washington companies in the technology, biotech, and cleantech sectors rolled up nearly $32 million in financing in September, according to data compiled by our partners at research firm CB Insights. Leading the way was RF Surgical Systems, a Bellevue-based company that raised $12 million last month. As Luke wrote last year, the company is working … Continue reading “WA Companies Raked in Nearly $32M in September Deals”
Xconomist of the Week: Phil Libin, Evernote, and the Death of the Exit
Xconomist Phil Libin, the CEO of Mountain View, CA-based Evernote, is a little unusual among his Silicon Valley brethren. He’s on the record as saying that the online notekeeping startup doesn’t want to be acquired. “There has never been an exit strategy at Evernote,” he wrote in an FAQ-style blog post after Evernote raised $50 … Continue reading “Xconomist of the Week: Phil Libin, Evernote, and the Death of the Exit”
EquaShip, Isilon, Tippr, Zaarly: Wrapping up a Week-Plus of Seattle Headlines
A pretty busy week in Seattle business means this weekly wrap of Seattle tech headlines is a little longer than normal: —EquaShip, the upstart shipping competitor hoping to outfox UPS and FedEx by consolidating parcels from small and medium-sized businesses, finally took the covers off its service last week. The company is led by CEO … Continue reading “EquaShip, Isilon, Tippr, Zaarly: Wrapping up a Week-Plus of Seattle Headlines”
Hipmunk, OnSwipe, MC10, Appature, Mimecast, and Northrop Grumman to Headline “6×6” Big Tech Ideas Conference Dec. 1
Daily deals and flash sales, please step off. Social-local-mobile recommendations, go fly a kite. Photo-sharing sites, go take a long walk off a short pier (and send me a picture). We don’t need more companies like those. Here’s what we need. Stretchy, bendy wearable computers. New tablet publishing models. High-altitude unmanned aerial vehicles (UAVs). The … Continue reading “Hipmunk, OnSwipe, MC10, Appature, Mimecast, and Northrop Grumman to Headline “6×6” Big Tech Ideas Conference Dec. 1″
Five Things I Learned at Startup School
Y Combinator has a brilliant franchise. It is called Startup School. This year it is at Stanford University on October 29 and co-hosted with BASES, the Business Association of Stanford Entrepreneurial Students. Some of Silicon Valley’s elite used to poo-poo Startup School as being too basic. I have always been in the camp supporting it. … Continue reading “Five Things I Learned at Startup School”
Atreaon and Arsenal Spinoff 480 Biomedical Nab Funds
Here are a couple of mid-week life sciences financings. —Watertown, MA-based Arsenal Medical, a developer of biomaterial-based scaffold and drug delivery products, announced it is spinning out a new company called 480 Biomedical. Both firms raised new funding ($15 million for 480 and $3 million for Arsenal) from Arsenal Medical’s return investors Polaris Venture Partners, … Continue reading “Atreaon and Arsenal Spinoff 480 Biomedical Nab Funds”
Ann Arbor’s Mobiata Opens New Offices in San Francisco, Twin Cities
Ann Arbor, MI-based startup Mobiata is growing, both in size and location. The Expedia-owned company, which develops mobile apps designed to make travel go more smoothly, just opened offices in San Francisco and the Minneapolis-St. Paul area—which is where the company started out in 2008 before relocating to Ann Arbor. Founder and General Manager Ben … Continue reading “Ann Arbor’s Mobiata Opens New Offices in San Francisco, Twin Cities”
Clearwire Shares Go for Another Ride on Word of Latest Sprint Plans
One thing you can say about having Sprint as a majority investor: It’s not boring. Shares of Kirkland, WA-based Clearwire (NASDAQ: [[ticker:CLWR]]) bounced up today after the third-quarter earnings report from Sprint (NYSE: [[ticker:S]]), particularly CEO Dan Hesse’s comments about a possible deal for Clearwire’s as-yet-unbuilt long-term evolution network. As quoted by Forbes’ Eric Savitz, … Continue reading “Clearwire Shares Go for Another Ride on Word of Latest Sprint Plans”
Biogen Idec’s Oral Multiple Sclerosis Drug Passes 2nd Major Test; Stock Soars
Biogen Idec’s new oral pill for multiple sclerosis passed its first pivotal trial back in April, and today the company got the confirmation it was looking for from a second major study. The Weston, MA-based biotech company (NASDAQ: [[ticker:BIIB]]) said today that dimethyl fumarate (BG-12) met its main goal of reducing multiple sclerosis flare-ups over … Continue reading “Biogen Idec’s Oral Multiple Sclerosis Drug Passes 2nd Major Test; Stock Soars”
The Web’s Last Word on Words
Wordnik (wərd-nik) noun. 1. A person associated with or characterized by a love of words, word usage, linguistics, or lexicography. 2. A startup company headquartered in San Mateo, California. Origin: word + -nik (Yiddish, from Russian). Cf. beatnik, peacenik. On the Internet, it’s hard to get people to slow down enough to use actual words, … Continue reading “The Web’s Last Word on Words”
IBM Names Virginia Rometty CEO and President
On Tuesday, IBM (NYSE: [[ticker:IBM]]) in Armonk, NY, said in a press statement there would be a changing of the guard at the onset of 2012. The company’s board elected Virginia Rometty to serve as CEO and president—as well as take a seat on the board—effective January 1. She succeeds Samuel J. Palmisano, who will … Continue reading “IBM Names Virginia Rometty CEO and President”
Onyx, Bayer’s Colon Cancer Drug Helps Extend Lives; Stock Climbs
Onyx Pharmaceuticals and Bayer settled a dispute a couple weeks ago about ownership of a certain colon cancer drug in development, and suddenly that colon cancer drug is looking like it could be pretty valuable. South San Francisco-based Onyx (NASDAQ: [[ticker:ONXX]]) said that its partner, Bayer, has stopped a pivotal clinical trial of regorafenib as … Continue reading “Onyx, Bayer’s Colon Cancer Drug Helps Extend Lives; Stock Climbs”
Ignition’s Cameron Myhrvold Joins the Lineup for Mobile Madness NW Dec. 6
We’re adding another name to the already power-packed list of speakers for Mobile Madness Northwest on Dec. 6: Cameron Myhrvold, founding partner at Ignition Partners. And speaking of Mobile Madness, you’ll want to buy your tickets now to get the best deal—the best rate expires today. Cameron knows his way around innovation in the Northwest … Continue reading “Ignition’s Cameron Myhrvold Joins the Lineup for Mobile Madness NW Dec. 6”
Emerald Biostructures Gets 3-Year Extension of UCB Drug Partnership
Emerald Biostructures‘ biggest customer is renewing its contract for another three years, and giving Emerald a piece of the action if it can help lay the foundation for new commercial drugs. Bainbridge Island, WA-based Emerald is announcing today that it has gotten a 3-year extension of its collaboration with UCB, a 3.2-billion-euro company in Belgium … Continue reading “Emerald Biostructures Gets 3-Year Extension of UCB Drug Partnership”
BIO Investor Forum Roundup: Immune Design, Sorbent Therapeutics, Epizyme
The best thing about coming to the BIO Investor Forum in San Francisco every year is the schmoozing with folks from all over the country in one place. The worst thing? There’s not much in the way of breaking news. Oh well, sometimes you gotta do the spade work on a slow news day if … Continue reading “BIO Investor Forum Roundup: Immune Design, Sorbent Therapeutics, Epizyme”
StarVest Partners’ Laura Sachar Talks About Bringing New York Savvy to the National Investment Scene
The fashion, advertising, and finance sectors are teeming with startups, but it takes more than a catchy gimmick to impress Laura Sachar, general partner with StarVest Partners in New York. She says her venture capital firm this year has made new investments across the country in prosaic but solid companies such as Seattle’s Lucid Commerce, … Continue reading “StarVest Partners’ Laura Sachar Talks About Bringing New York Savvy to the National Investment Scene”
Hadapt Gets Series A, Cisco Buys BNI, Cubist Acquisition of Adolor Valued at $415M, & More Boston-Area Deals News
Financing rounds, acquisitions, and business plan prizes have made up the New England deals news this week. —Continuing the West-Coast-company-buys-East-Coast-company trend of last week, San Jose, CA-based Cisco Systems announced its purchase of Boxborough, MA-based BNI Video, a developer of software for managing cable content on the back end and improving the browsing experience for … Continue reading “Hadapt Gets Series A, Cisco Buys BNI, Cubist Acquisition of Adolor Valued at $415M, & More Boston-Area Deals News”
Cubist Says Adolor Deal Offers “Free Option on Billion-Dollar Program”
Lexington, MA-based Cubist Pharmaceuticals (NASDAQ: [[ticker:CBST]]) had its eye on Adolor (NASDAQ: [[ticker:ADLR]]) long before it announced it would acquire the Exton, PA-based company on Monday. But it wasn’t until drug giant GlaxoSmithKline (NYSE: [[ticker:GSK]]) pulled out of a co-promotion deal with Adolor in June that Cubist could finally pounce. Glaxo and Adolor were partnered on a … Continue reading “Cubist Says Adolor Deal Offers “Free Option on Billion-Dollar Program””
Playmark Opens Digital Licensing Shop with Rights to 2,000 NFL Players
Professional athletes marketing their mugs in endorsements is nothing new. But the explosion of digital goods and micro-entrepreneurs has opened up a ton of new ways for sports stars to make their mark, such as the mobile apps and games from the likes of Chad Ochocinco and Mike Tyson. Seattle startup Playmark is hoping to … Continue reading “Playmark Opens Digital Licensing Shop with Rights to 2,000 NFL Players”
iRobot Lays Off About 55 Staff in Advance of Q3 Earnings Report
[Updated 4:35 pm] Bedford, MA-based iRobot laid off about 55 people last week from its government and industrial robots division, Xconomy has learned. I heard from a source familiar with the company that some of the layoffs came to light because ex-employees posted on social media looking for new positions. An iRobot spokesperson did not … Continue reading “iRobot Lays Off About 55 Staff in Advance of Q3 Earnings Report”
UW Prof’s Startup Rolls out Smart Thermostats, Inspired by Apple’s Iconic Devices
In her work at the University of Washington, Yoky Matsuoka spends time figuring out how to make the brain work directly with machines. In her startup work, she’s targeting something a lot less fancy-sounding: the home thermostat. Matsuoka is vice president of technology at Nest, a Palo Alto, CA-based startup aiming to tackle energy efficiency … Continue reading “UW Prof’s Startup Rolls out Smart Thermostats, Inspired by Apple’s Iconic Devices”
Computing in the Age of the $1,000 Genome: Some Themes and Some Photos
Scientists will soon be able to obtain the full 6 billion letter string of DNA that makes us who we are for $1,000, and the cost might drop all the way to $100 or less. Probably 1 billion people will get their DNA sequenced when prices go that low. It’s a big opportunity with big … Continue reading “Computing in the Age of the $1,000 Genome: Some Themes and Some Photos”
Life Is Good, Listen to People, and More Takeaways from Bert Jacobs at MassChallenge
Life is not good when you lose your notes from one of the best keynotes you’ve seen in a while. In fact, life kind of sucks. Nevertheless, I will recount my top five takeaways from Bert Jacobs, the co-founder and CEO of Life Is Good, the Boston-based apparel maker and retail brand. He spoke at … Continue reading “Life Is Good, Listen to People, and More Takeaways from Bert Jacobs at MassChallenge”
Illumina To Cut 200 Jobs, 8 Percent of Workforce, After Third Quarter Sales Fall Short
[Updated: 6:45 am, 10/26] San Diego-based Illumina is doing some restructuring to make up for third-quarter sales that fell way short of investors’ expectations. The market-leading maker of DNA sequencing instruments (NASDAQ: [[ticker:ILMN]]) said today it is going to restructure (i.e., make job cuts) that will add up to a $15 million to $17 million … Continue reading “Illumina To Cut 200 Jobs, 8 Percent of Workforce, After Third Quarter Sales Fall Short”
VC Slows, ViaSat Soars, Wests Unveil $100M Healthtech Fund, & More San Diego BizTech News
Data on venture capital investment activity during the third quarter poured in from different sources last week. The highlights are here, along with the rest of the San Diego’s biztech news. —Total venture capital invested in San Diego startups so far this year amounted to $567.7 million in 82 deals, according to the MoneyTree Report … Continue reading “VC Slows, ViaSat Soars, Wests Unveil $100M Healthtech Fund, & More San Diego BizTech News”
MPM-Backed Rhythm Advances Drug Programs in Diabetes and Obesity
When Boston-based Rhythm Pharmaceuticals started up in 2010 with a plan to develop drugs to address diabetes and obesity, the biotech world was littered with companies struggling to make a mark in those disease areas. San Diego based Arena Pharmaceuticals was fighting to produce data for the FDA showing its obesity drug was safe. Phenomix, … Continue reading “MPM-Backed Rhythm Advances Drug Programs in Diabetes and Obesity”
Kgbdeals and Mobile Spinach Hunt for Opportunities in Troubled Daily Deals Market
In spite of companies crumbling in the daily deals space, New York’s kgbdeals and San Mateo, CA’s Mobile Spinach believe they can survive in this now-brutal sector. Kgbdeals, part of directory assistance company kgb, acquired New York’s TheDealist last Wednesday to expand its reach with customers. Before kgbdeals could uncork the champagne, a rival deals … Continue reading “Kgbdeals and Mobile Spinach Hunt for Opportunities in Troubled Daily Deals Market”
Imagen Biotech, Staffed With Eyetech Vets, Launches in NYC With Plan to Tackle Eye Diseases
Nearly a week after announcing its $40 million Series A financing, New York-based Imagen Biotech is still largely in stealth mode. But the startup’s chief medical officer, Matthew Feinsod, took a few minutes yesterday to talk with Xconomy about one of Imagen’s top priorities: finding new drugs to treat “dry” age-related macular degeneration (AMD), a … Continue reading “Imagen Biotech, Staffed With Eyetech Vets, Launches in NYC With Plan to Tackle Eye Diseases”
Zaarly Rings Up $14M to Fuel Growth, adds Firepower to Board with HP’s Meg Whitman
Peer-to-peer e-commerce startup Zaarly, born out of a Startup Weekend event just this spring, has tallied a new $14.1 million venture round and is adding freshly installed Hewlett-Packard chief Meg Whitman to its board. The news represents some pretty high-profile votes of confidence in Zaarly, which has only been around as a functioning product for … Continue reading “Zaarly Rings Up $14M to Fuel Growth, adds Firepower to Board with HP’s Meg Whitman”
SiOnyx, Black Silicon Startup of the North Shore, Shows Its Solar Cell Tech Is For Real
In a very difficult climate for U.S. solar companies, one Boston-area startup has made some significant progress in solar technology. SiOnyx, a Beverly, MA-based semiconductor company known for its “black silicon” approach to various applications, including solar cells, is reporting today that it has achieved an overall efficiency that is higher than the current industry … Continue reading “SiOnyx, Black Silicon Startup of the North Shore, Shows Its Solar Cell Tech Is For Real”
MassChallenge Awards $100K to Alkeus, Sanergy, and Tinfoil; 14 Others Get $50K in Accelerator Program’s Second Year
Another year, another MassChallenge class. The sophomore edition of the startup accelerator and $1 million business plan competition did not disappoint. Nor did the final event of the program. Tonight was the big awards gala, held at the Boston Convention & Exhibition Center in South Boston—a cavernous and sprawling, impersonal space—but it did the job. … Continue reading “MassChallenge Awards $100K to Alkeus, Sanergy, and Tinfoil; 14 Others Get $50K in Accelerator Program’s Second Year”
They’re Under 30. They Probably Can.
It’s getting tiring to hear that the United States can’t. Can’t innovate anymore. Can’t create jobs. But if you look around Massachusetts I think you’ll come to the conclusion that if anyone can, it’s probably people under 30 (plus or minus). I’m sitting in an old mill building in Holyoke. There are almost 100,000 students … Continue reading “They’re Under 30. They Probably Can.”